STOCK TITAN

Grifois, S.A. (GRFS) Financials

GRFS
FY2025 annual
Revenue $206.0M YoY not available
Net Income $6.0M YoY not available
EPS (Diluted) Not reported for FY2025
Free Cash Flow Not reported for FY2025
Market Cap $5.1B as of Oct 9, 2026
Price / Sales 24.6x on $206.0M revenue, FY2025
Price / Earnings 846x on $6.0M net income, FY2025
Price / Book n/m negative shareholder equity, so no book multiple, FY2025

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Apr 17, 2026 Reported Currency USD FYE April

Newest figures come from the 10-K for FY2025, filed Apr 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GRFS SEC filings page.

Grifois, S.A. (GRFS) reported $206.0M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GRFS FY2025

Grifols reported a small profit on an asset-light base, but liabilities exceeded assets and short-term obligations exceeded current resources.

The combination of a 2.9% net margin and 7.4% return on assets suggests FY2025 earnings were positive but modest relative to sales, while the balance sheet carried negative equity. That structure means reported profitability coexisted with limited balance-sheet protection for creditors and shareholders.

At $206M of revenue against $81M of assets, the business generated more than two and a half times its asset base in annual sales; this points to an asset-light operating model rather than heavy investment in owned assets.

A 0.6x current ratio means current liabilities of $47M exceeded current assets of $27M, while total liabilities of $103M exceeded assets. The $6M net income therefore did not translate into positive reported equity, which is a materially different picture from the income statement alone.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

Grifois, S.A. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$206.0M

Grifois, S.A. generated $206.0M in revenue in fiscal year 2025.

Net Income
$6.0M

Grifois, S.A. reported $6.0M in net income in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

EPS (Diluted)

Not reported for fiscal year 2025.

Cash & Balance Sheet

Cash & Debt
Debt $8.0M

Grifois, S.A. carried $8.0M in long-term debt as of fiscal year 2025; cash and equivalents are not reported for that period.

Shares Outstanding
426M

Grifois, S.A. had 426M shares outstanding in fiscal year 2025.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Net Margin
2.9%

Grifois, S.A.'s net profit margin was 2.9% in fiscal year 2025, showing the share of revenue converted to profit.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

None of these metrics is reported for fiscal year 2025.

GRFS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRFS annual income statement
MetricFY2510-K
Revenue$206.0M
Net Income$6.0M
Diluted Shares (Avg)682M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, EPS (Basic), EPS (Diluted).

GRFS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRFS annual balance sheet
MetricFY2510-K
Total Assets$81.0M
Current Assets$27.0M
Total Liabilities$103.0M
Current Liabilities$47.0M
Non-Current Liabilities$56.0M
Long-Term Debt$8.0M
Total Equity-$28.0M

Not reported in any period shown, so not listed: Cash & Equivalents, Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Retained Earnings.

GRFS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GRFS annual financial ratios
MetricFY2510-K
Net Margin2.9%
Return on Assets7.4%
Current Ratio0.57
Asset Turnover2.54

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Return on Equity, Debt-to-Equity, FCF Margin.

Note: Shareholder equity is negative (-$28.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.57), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Grifois, S.A. GRFS FY2025 $206.0M $6.0M 2.9% $5.1B —
Organon & Co. OGN FY2025 $6.2B $187.0M 3.0% $3.6B 25/100
Elanco Animal Health Incorporated ELAN FY2025 $4.7B -$232.0M -4.9% $11.2B 36/100
Biogen Inc. BIIB FY2025 $9.9B $1.3B 13.1% $32.8B 43/100
Pfizer Inc. PFE FY2025 $62.6B $7.8B 12.4% $159.6B 33/100

Frequently Asked Questions

What is Grifois, S.A.'s annual revenue?

Grifois, S.A. (GRFS) reported $206.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Grifois, S.A. profitable?

Yes, Grifois, S.A. (GRFS) reported a net income of $6.0M in fiscal year 2025, with a net profit margin of 2.9%.

What is Grifois, S.A.'s net profit margin?

Grifois, S.A. (GRFS) had a net profit margin of 2.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Grifois, S.A. (GRFS) had $81.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Grifois, S.A. (GRFS) had 426M shares outstanding as of fiscal year 2025.

Grifois, S.A. (GRFS) had a current ratio of 0.57 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Grifois, S.A. (GRFS) had a return on assets of 7.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Grifois, S.A. (GRFS) trades at 846x earnings, its market capitalization divided by net income of $6.0M net income, FY2025. The market capitalization is $5.1B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Grifois, S.A. (GRFS) trades at 24.6x sales, its market capitalization divided by revenue of $206.0M revenue, FY2025. The market capitalization is $5.1B as of Oct 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Grifois, S.A. (GRFS) has negative shareholder equity of -$28.0M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Back to top